Filing Flows › Comparisons › ACOG vs TSHA
Alpha Cognition vs Taysha Gene Therapies: ACOG and TSHA compared
Alpha Cognition is the larger company: $6.1M of revenue in its latest quarter (Q2 2026) against $5.5M for Taysha Gene Therapies (Q4 2025). Alpha Cognition is growing faster (+268% against +171% a year earlier). Alpha Cognition is more profitable, with an operating margin of -127.3% against -516.0%.
Where the money goes: ACOG and TSHA
Alpha Cognition (ACOG) · Q2 2026
Alpha Cognition, Q2 2026: revenue $6.1M (+268% year over year), operating margin -127.3%, net loss $8.8M, operating cash flow −$6.9M. The chart follows the revenue to costs, profit and cash.
Taysha Gene Therapies (TSHA) · Q4 2025
Taysha Gene Therapies, Q4 2025: revenue $5.5M (+171% year over year), operating margin -516.0%, net loss $27.9M, operating cash flow −$26.7M. The chart follows the revenue to costs, profit and cash.
| Alpha Cognition (ACOG) | Taysha Gene Therapies (TSHA) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q4 2025 |
| Revenue | $6.1M | $5.5M |
| Revenue growth, Y/Y | +268% | +171% |
| Operating margin | -127.3% | -516.0% |
| Net earnings | −$8.8M | −$27.9M |
| Net margin | -144.3% | -507.8% |
| Operating cash flow | −$6.9M | −$26.7M |
Where the revenue comes from
Alpha Cognition
- Product, net: $6.0M (99%)
- Licensing: $51K (1%)
Questions
Which is bigger, Alpha Cognition or Taysha Gene Therapies?
Alpha Cognition is the larger company: $6.1M of revenue in its latest quarter (Q2 2026) against $5.5M for Taysha Gene Therapies (Q4 2025).
Is Alpha Cognition or Taysha Gene Therapies growing faster?
Alpha Cognition is growing faster (+268% against +171% a year earlier).
Which is more profitable, Alpha Cognition or Taysha Gene Therapies?
Alpha Cognition is more profitable, with an operating margin of -127.3% against -516.0%.
More: Alpha Cognition earnings · how Alpha Cognition makes money · Taysha Gene Therapies earnings · how Taysha Gene Therapies makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-K filed Mar 19, 2026). Fiscal quarters can end on different dates. Not investment advice.